Literature DB >> 16766542

Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis.

Jan T Kielstein1, Shelley R Salpeter, Stefanie M Bode-Boeger, John P Cooke, Danilo Fliser.   

Abstract

BACKGROUND: Dosing of most drugs must be adapted in renal insufficiency, making accurate assessment of renal function essential in clinical medicine. Furthermore, even modest impairment of renal function has been recognized as a cardiovascular risk factor. The purpose of this analysis was to identify the role of symmetric dimethylarginine (SDMA), the structural isomer of the cardiovascular risk marker asymmetric dimethylarginine, as an endogenous marker of renal function.
METHODS: Comprehensive searches of Medline and the Cochrane Library from 1970 to February 2006 were performed to identify studies that evaluated the correlation between SDMA and renal function. The search was augmented by scanning references of identified articles and reviews. The correlation coefficients (R) were recorded from each study for the values of 1/SDMA and clearance estimates and for SDMA and creatinine levels. The summary correlation coefficients with 95% confidence intervals (CIs) were pooled using the random-effects method.
RESULTS: In 18 studies involving 2136 patients systemic SDMA concentrations correlated highly with inulin clearance [R = 0.85 (CI 0.76-0.91, P < 0.0001)], as well as with various clearance estimates combined [R = 0.77 (CI 0.65-0.85, P < 0.0001)] and serum creatinine [R = 0.75 (CI 0.46-089, P < 0.0001)].
CONCLUSIONS: SDMA exhibits some properties of a reliable marker of renal function. Future studies have to clarify whether SDMA is indeed suited to improve diagnosis and eventually optimize care of patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16766542     DOI: 10.1093/ndt/gfl292

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  110 in total

1.  Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease.

Authors:  Takhar Kasumov; John M Edmison; Srinivasan Dasarathy; Carole Bennett; Rocio Lopez; Satish C Kalhan
Journal:  Metabolism       Date:  2010-09-23       Impact factor: 8.694

2.  Serum Asymmetric and Symmetric Dimethylarginine and Morbidity and Mortality in Hemodialysis Patients.

Authors:  Tariq Shafi; Thomas H Hostetter; Timothy W Meyer; Seungyoung Hwang; Xin Hai; Michal L Melamed; Tanushree Banerjee; Josef Coresh; Neil R Powe
Journal:  Am J Kidney Dis       Date:  2017-01-12       Impact factor: 8.860

3.  Simultaneous bioanalysis of L-arginine, L-citrulline, and dimethylarginines by LC-MS/MS.

Authors:  Soyoung Shin; Sun-Mi Fung; Srinidi Mohan; Ho-Leung Fung
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-01-14       Impact factor: 3.205

4.  Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.

Authors:  Eva Schepers; Daniela V Barreto; Sophie Liabeuf; Griet Glorieux; Sunny Eloot; Fellype C Barreto; Ziad Massy; Raymond Vanholder
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-04       Impact factor: 8.237

5.  Nested case-control study of one-carbon metabolites in mid-pregnancy and risks of cleft lip with and without cleft palate.

Authors:  Gary M Shaw; Stein Emil Vollset; Suzan L Carmichael; Wei Yang; Richard H Finnell; Henk Blom; Per M Ueland
Journal:  Pediatr Res       Date:  2009-11       Impact factor: 3.756

6.  Contribution of symmetric dimethylarginine to GFR decline in pediatric chronic kidney disease.

Authors:  Ellen R Brooks; Shannon Haymond; Alfred Rademaker; Christopher Pierce; Irene Helenowski; Rod Passman; Faye Vicente; Bradley A Warady; Susan L Furth; Craig B Langman
Journal:  Pediatr Nephrol       Date:  2017-12-07       Impact factor: 3.714

7.  Dimethylarginines and inflammation markers in patients with chronic kidney disease undergoing dialysis.

Authors:  Yildiz Oner-Iyidogan; Pernur Oner; Hikmet Kocak; Figen Gurdol; Seldag Bekpinar; Yesim Unlucerci; Yasar Caliskan; Pinar Cetinalp-Demircan; Taner Kocak; Aydin Turkmen
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

8.  Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis.

Authors:  Ayse L Mindikoglu; Antone R Opekun; William E Mitch; Laurence S Magder; Robert H Christenson; Thomas C Dowling; Matthew R Weir; Stephen L Seliger; Charles D Howell; Jean-Pierre Raufman; Abbas Rana; John A Goss; Saira A Khaderi; John M Vierling
Journal:  Dig Dis Sci       Date:  2018-02-01       Impact factor: 3.199

9.  Changes in arginine are inversely associated with type 2 diabetes: A case-cohort study in the PREDIMED trial.

Authors:  Edward Yu; Miguel Ruiz-Canela; Cristina Razquin; Marta Guasch-Ferré; Estefania Toledo; Dong D Wang; Christopher Papandreou; Courtney Dennis; Clary Clish; Liming Liang; Monica Bullo; Dolores Corella; Montserrat Fitó; Mario Gutiérrez-Bedmar; José Lapetra; Ramón Estruch; Emilio Ros; Montserrat Cofán; Fernando Arós; Dora Romaguera; Lluis Serra-Majem; Jose V Sorlí; Jordi Salas-Salvadó; Frank B Hu; Miguel A Martínez-González
Journal:  Diabetes Obes Metab       Date:  2018-10-02       Impact factor: 6.577

10.  Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT).

Authors: 
Journal:  BMC Pediatr       Date:  2009-12-17       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.